Eiz-Vesper B, Bonig H
Transfus Med Hemother. 2025; 52(1):1-4.
PMID: 39944410
PMC: 11813275.
DOI: 10.1159/000543415.
Elzein H
Cureus. 2024; 16(3):e56812.
PMID: 38654809
PMC: 11036791.
DOI: 10.7759/cureus.56812.
Meher M, Gupta S, Singh A, Kumar P, Kumar S, Amrit A
J Family Med Prim Care. 2022; 11(7):3449-3454.
PMID: 36387650
PMC: 9648264.
DOI: 10.4103/jfmpc.jfmpc_2167_21.
Liu J, Tokheim C, Lee J, Gan W, North B, Liu X
Nat Commun. 2021; 12(1):6704.
PMID: 34795215
PMC: 8602260.
DOI: 10.1038/s41467-021-26871-y.
Kamijo K, Shimomura Y, Yamashita D, Ishikawa T
Case Rep Oncol. 2021; 14(2):1139-1143.
PMID: 34413745
PMC: 8339493.
DOI: 10.1159/000517442.
Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia.
Sobash P, Guddati A, Kota V
Case Rep Oncol. 2020; 13(2):534-537.
PMID: 32518550
PMC: 7265745.
DOI: 10.1159/000506895.
Dasatinib inhibits peripapillary scleral myofibroblast differentiation.
Chow A, McCrea L, Kimball E, Schaub J, Quigley H, Pitha I
Exp Eye Res. 2020; 194:107999.
PMID: 32179077
PMC: 7217736.
DOI: 10.1016/j.exer.2020.107999.
What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?.
Bosi G, Fogliatto L, Costa T, Grokoski K, Pereira M, Bugs N
Hematol Transfus Cell Ther. 2019; 41(3):222-228.
PMID: 31085148
PMC: 6732531.
DOI: 10.1016/j.htct.2018.11.005.
Translocation-Related Sarcomas.
Nakano K, Takahashi S
Int J Mol Sci. 2018; 19(12).
PMID: 30487384
PMC: 6320865.
DOI: 10.3390/ijms19123784.
Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia.
Machado-Alba J, Machado-Duque M
Int J Clin Pharm. 2017; 39(4):851-859.
PMID: 28508322
DOI: 10.1007/s11096-017-0484-9.
[The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition)].
Zhonghua Xue Ye Xue Za Zhi. 2016; 37(8):633-9.
PMID: 27587241
PMC: 7348542.
DOI: 10.3760/cma.j.issn.0253-2727.2016.08.001.
Therapeutic strategies targeting cancer stem cells.
Yoshida G, Saya H
Cancer Sci. 2015; 107(1):5-11.
PMID: 26362755
PMC: 4724810.
DOI: 10.1111/cas.12817.
Electrolyte disturbances and acute kidney injury induced by imatinib therapy.
de Oliveira R, Marques I, Seguro A, Andrade L
NDT Plus. 2015; 2(1):27-9.
PMID: 25949279
PMC: 4421484.
DOI: 10.1093/ndtplus/sfn188.
How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health.
Kuznetsov V, Lee H, Maurer-Stroh S, Molnar M, Pongor S, Eisenhaber B
Health Inf Sci Syst. 2015; 1:2.
PMID: 25825654
PMC: 4336111.
DOI: 10.1186/2047-2501-1-2.
Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome.
Rizzo A, Aman J, van Nieuw Amerongen G, Dudek S
Arterioscler Thromb Vasc Biol. 2015; 35(5):1071-9.
PMID: 25814671
PMC: 4655821.
DOI: 10.1161/ATVBAHA.115.305085.
Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report.
Lai S, Huang T, Chen J, Wu Y, Chang P
Oncol Lett. 2015; 9(4):1957-1961.
PMID: 25789076
PMC: 4356413.
DOI: 10.3892/ol.2015.2928.
Improved prediction of clinical outcome in chronic myeloid leukemia.
Cojbasic I, Macukanovic-Golubovic L, Mihailovic D, Vucic M, Lukic S
Int J Hematol. 2014; 101(2):173-83.
PMID: 25540066
DOI: 10.1007/s12185-014-1726-4.
Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma.
Li N, Maly D, Chanthery Y, Sirkis D, Nakamura J, Berger M
Mol Cancer Ther. 2014; 14(2):419-28.
PMID: 25522764
PMC: 4326592.
DOI: 10.1158/1535-7163.MCT-14-0526.
Assessment of interleukin 1β serum level in different responder groups and stages of chronic myeloid leukemia patients on imatinb mesylate therapy.
Matti B, Saleem M, Sabir S
Indian J Hematol Blood Transfus. 2014; 30(4):247-52.
PMID: 25435722
PMC: 4243414.
DOI: 10.1007/s12288-014-0339-7.
Bringing cancer care to the poor: experiences from Rwanda.
Shulman L, Mpunga T, Tapela N, Wagner C, Fadelu T, Binagwaho A
Nat Rev Cancer. 2014; 14(12):815-21.
PMID: 25355378
DOI: 10.1038/nrc3848.
